WO2021125822A1 - Composition destinée à soulager la gueule de bois, contenant du pediococcus inopinatus comme principe actif - Google Patents

Composition destinée à soulager la gueule de bois, contenant du pediococcus inopinatus comme principe actif Download PDF

Info

Publication number
WO2021125822A1
WO2021125822A1 PCT/KR2020/018518 KR2020018518W WO2021125822A1 WO 2021125822 A1 WO2021125822 A1 WO 2021125822A1 KR 2020018518 W KR2020018518 W KR 2020018518W WO 2021125822 A1 WO2021125822 A1 WO 2021125822A1
Authority
WO
WIPO (PCT)
Prior art keywords
culture
strain
composition
alcoholic
wikim0108
Prior art date
Application number
PCT/KR2020/018518
Other languages
English (en)
Korean (ko)
Inventor
채성욱
심기석
홍성욱
노성운
황혜련
이호재
Original Assignee
한국 한의학 연구원
한국식품연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국 한의학 연구원, 한국식품연구원 filed Critical 한국 한의학 연구원
Publication of WO2021125822A1 publication Critical patent/WO2021125822A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/14—Extraction

Definitions

  • the present invention relates to a hangover relieving composition
  • a hangover relieving composition comprising Pediococcus inofinatus as an active ingredient.
  • Drinking alcohol until drunkenness may cause nutrient deficiency (blood sugar, mineral and vitamin deficiency) due to toxicity, dehydration, and malabsorption of alcohol and its intermediate metabolite, acetaldehyde, and individual variations (genetic predisposition) , and environmental conditions (nutrition status, exercise status, degree of dehydration, health status, etc.)
  • nutrient deficiency blood sugar, mineral and vitamin deficiency
  • acetaldehyde and individual variations (genetic predisposition)
  • environmental conditions nutrition status, exercise status, degree of dehydration, health status, etc.
  • Alcohol is oxidized to acetaldehyde in the liver by alcohol dehydrogenase (ADH) and the coenzyme NAD + , and acetaldehyde is decomposed to acetic acid by aldehyde dehydrogenase (ALDH) and NAD +.
  • ADH alcohol dehydrogenase
  • ALDH aldehyde dehydrogenase
  • NAD + aldehyde dehydrogenase
  • cytochrome, P-450 type 2E1 (CYP2E1) cytochrome
  • Acetaldehyde and acetic acid cause cytotoxicity, headache or abdominal pain, and dehydration due to changes in osmotic pressure through lipid peroxidation.
  • excessive alcohol consumption can cause gastrointestinal diseases, which in severe cases can cause gastritis or stomach ulcers.
  • Korean Patent No. 1673450 discloses a probiotic composition including a Pediococcus pentosaceus KID7 strain having a cholesterol lowering effect
  • Korean Patent No. 1611829 discloses obesity and obesity caused by Pediococcus pentosaceus CBT SL4 strain for the prevention or treatment of metabolic diseases and a composition comprising the same are disclosed, but disclosed for a hangover relieving composition comprising Pediococcus inofinatus of the present invention as an active ingredient no bar
  • the present invention has been derived by the above needs, and the present invention provides a hangover relieving composition comprising Pediococcus inofinatus as an active ingredient, and Pediococcus inofinatus WiKim0108 is not only not cytotoxic, but also , by reducing the content of ethanol and acetaldehyde in blood increased by ingestion of alcohol, and confirming that there is a gastrointestinal protective function as well as effectively increasing blood ADH and ALDH activity, thereby completing the present invention.
  • the present invention Pediococcus inopinatus ( Pediococcus inopinatus ) Wikim0108 strain (Accession No.: KACC 81091BP), the culture of the strain, the concentrate of the culture, the dried product of the culture and the extract of the culture It provides a health functional food composition for the prevention or improvement of hangover relieving or alcoholic gastrointestinal disease comprising at least one selected from among as an active ingredient.
  • Pediococcus inopinatus Pediococcus inopinatus
  • WiKim0108 strain accesion No.: KACC 81091BP
  • the culture of the strain the concentrate of the culture, the dried product of the culture, and at least one selected from the extract of the culture It provides a pharmaceutical composition for the prevention or treatment of hangover relieving or alcoholic gastrointestinal disease comprising as an active ingredient.
  • the present invention relates to a hangover relieving composition
  • a hangover relieving composition comprising Pediococcus inofinatus as an active ingredient.
  • Pediococcus inofinatus WiKim0108 not only has no cytotoxicity, but also reduces the content of ethanol and acetaldehyde in blood increased by ingestion of alcohol, and effectively increases blood ADH and ALDH activity as well as gastrointestinal protective function. Therefore, the composition of the present invention can be usefully used as a health functional food or medicine for hangover relieving or alcoholic gastrointestinal disease.
  • 1 shows the relative ADH activity of 8 samples selected from among lactic acid bacteria isolated from skate kimchi.
  • liver cancer cell line HepG 2 Pediococcus inofinatus WiKim0108 strain.
  • N is a normal cell untreated.
  • G5 is a result of confirming the contents of ethanol (A) and acetaldehyde (B) in serum after administration of the Pediococcus inofinatus WiKim0108 strain of the present invention and 2 hours after ethanol administration.
  • G1 is a normal group untreated
  • G2 is an ethanol (40% EtOH, 3g/kg) administration group
  • G3 is a positive control group administered with YM (a commercial substance for hangover relief) before ethanol administration
  • G4 is a positive control group before ethanol administration
  • Pediococcus inofinatus WiKim0108 strain of the present invention 1 ⁇ 10 8 CFU / head administered group.
  • G1 is a normal group untreated
  • G2 is an ethanol (40% EtOH, 3g/kg) administration group
  • G3 is a positive control group administered with YM (a commercial substance for hangover relief) before ethanol administration
  • G4 is a positive control group before ethanol administration Pediococcus inofinatus WiKim0108 strain of the present invention 1 ⁇ 10 8 CFU / head administered group.
  • ADH or ALDH activity in the serum of the alcohol-administered group was statistically significantly decreased compared to the normal group, p ⁇ 0.001, and **, *** are Pediococcus inofinatus WiKim0108 of the present invention compared to the alcohol-administered group
  • the ADH or ALDH activity in the serum of the strain-administered group or the positive control group was statistically significantly increased, with ** being p ⁇ 0.01 and *** being p ⁇ 0.001.
  • FIG. 7 is an H&E staining result (A) confirming the gastrointestinal protective effect according to the administration of the Pediococcus inofinatus WiKim0108 strain of the present invention and, in the staining result, the area of the gastric pits cells (B) and the submucosa
  • the area (C) is quantified.
  • # indicates that the gastric pits cell area of the alcohol-administered group (G2) decreased compared to the normal group (G1), and p ⁇ 0.05, and ## indicates that the submucosal cell area of the alcohol-administered group (G2) increased compared to the normal group (G1). p ⁇ 0.01.
  • the present invention is Pediococcus inopinatus ( Pediococcus inopinatus ) Wikim0108 strain (Accession No.: KACC 81091BP), the culture of the strain, the concentrate of the culture, the dried product of the culture and at least one selected from the extract of the culture is effective It relates to a health functional food composition for the prevention or improvement of hangover relieving or alcoholic gastrointestinal disease comprising as a component.
  • the Pediococcus inofinatus WiKim0108 strain is preferably isolated from skate or skate kimchi, and more preferably from skate kimchi, but is not limited thereto.
  • the extract of the Pediococcus inofinatus WiKim0108 strain culture may be prepared by a method comprising the following steps, but is not limited thereto:
  • step (3) Concentrating the filtered extract of step (2) under reduced pressure and drying to prepare an extract.
  • the extraction solvent in step (1) is preferably selected from water, C 1 to C 4 lower alcohols or mixtures thereof, more preferably methanol, but is not limited thereto.
  • the extraction method may use all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction.
  • the extraction solvent is preferably extracted by adding 1 to 20 times the weight of the Pediococcus inofinatus WiKim0108 strain culture, and more preferably adding 5 to 15 times.
  • the extraction temperature is preferably 20 ⁇ 110 °C, but is not limited thereto.
  • the extraction time is preferably 0.5 to 10 hours, but is not limited thereto.
  • the vacuum concentration in step (3) is preferably, but not limited to, a vacuum vacuum concentrator or a vacuum rotary evaporator.
  • drying under reduced pressure, vacuum drying, boiling drying, spray drying or freeze drying is preferable, but is not limited thereto.
  • hangover is caused by a lack of alcohol dehydrogenase (ADH) or aldehyde dehydrogenase (ALDH) that decomposes acetaldehyde in the state of being very drunk, or the accumulation of alcohol or acetaldehyde in the body due to low activity.
  • ADH alcohol dehydrogenase
  • ADH aldehyde dehydrogenase
  • ALDH aldehyde dehydrogenase
  • the representative symptom may be at least one selected from nausea, dizziness, vomiting, thirst, lethargy, headache, muscle pain, indigestion, abdominal pain, and diarrhea.
  • the alcoholic gastrointestinal disease is preferably nausea, vomiting, abdominal pain, indigestion, alcoholic gastritis or alcoholic gastric ulcer, but is not limited thereto.
  • the active ingredient promotes the decomposition of alcohol and acetaldehyde in the blood, and can increase the activity of alcohol dehydrogenase or aldehyde dehydrogenase.
  • the active ingredient is preferably prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto.
  • the strain or its culture medium of the present invention When used as a health functional food composition, the strain or its culture solution may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • the active ingredient may be suitably determined according to the intended use (prophylactic, health or therapeutic treatment).
  • the health functional food composition of the present invention may further include an ingredient that is commonly added during food production and is pharmaceutically acceptable.
  • an ingredient that is commonly added during food production and is pharmaceutically acceptable for example, when prepared as a beverage, in addition to the strain of the present invention, one or more components may be additionally included in citric acid, high fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and the like.
  • the amount that can be included as an active ingredient of the health functional food composition according to the present invention is appropriately selected according to the age, sex, weight, condition, and symptoms of the disease of a person who wants a health functional food for relieving a hangover or preventing or improving alcoholic gastrointestinal disease.
  • it is recommended to contain about 0.01 to 10.0 g per day for adults, and by ingesting food having such content, it is possible to obtain the effect of relieving a hangover or preventing or improving alcoholic gastrointestinal diseases.
  • the present invention Pediococcus inopinatus ( Pediococcus inopinatus ) WiKim0108 strain (Accession No.: KACC 81091BP), the culture of the strain, the concentrate of the culture, the dried product of the culture, and at least one selected from the extract of the culture It relates to a pharmaceutical composition for the prevention or treatment of hangover relieving or alcoholic gastrointestinal disease comprising as an active ingredient.
  • the pharmaceutical composition may further include one or more selected from suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
  • suitable carriers excipients and diluents commonly used in the preparation of pharmaceutical compositions.
  • the pharmaceutical composition according to the present invention is formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions, respectively, according to a conventional method.
  • Carriers, excipients and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, various compounds or mixtures including calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. .
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the strain or the vesicles derived from the strain, for example, starch, calcium carbonate , sucrose or lactose, gelatin, etc. are mixed and prepared.
  • lubricants such as magnesium stearate and talc are also used.
  • Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, etc.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, etc. can be used.
  • the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, and the term 'pharmaceutically effective amount' as used herein means sufficient to prevent or treat a disease at a reasonable benefit/risk ratio applicable to medical prevention or treatment.
  • the amount, and the effective dose level is the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration of the composition of the present invention used, the route of administration and the rate of excretion, the treatment
  • the duration may be determined according to factors including drugs used in combination with or concurrently with the composition of the present invention and other factors well known in the medical arts.
  • the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. and may be administered single or multiple. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects.
  • the frequency of administration of the composition of the present invention is not particularly limited thereto, but may be administered once a day or administered several times in divided doses.
  • the above dosage does not limit the scope of the present invention in any way.
  • the administration route of the pharmaceutical composition may be administered through any general route as long as it can reach the target tissue.
  • the pharmaceutical composition of the present invention is not particularly limited thereto, and may be administered through routes such as oral administration and rectal administration, and in some cases may be administered by other routes depending on the purpose.
  • the oral composition should be formulated to coat the active agent or to protect it from degradation in the stomach.
  • the composition may be administered by any device capable of transporting the active agent to a target cell.
  • each isolate was cultured in an MRS liquid medium at 30°C for 24 hours under anaerobic conditions and centrifuged (4,000 ⁇ 15 minutes, 4°C). After that, the culture supernatant was separated.
  • reaction solution for ADH activity analysis was 0.15 ml of ADH (1 unit, Sigma Chem. Co., USA), 0.75 ml of Tris-HCl buffer (1M, pH 8.8), 0.3 ml of NAD + (20 mM), 0.1 ml It was prepared by mixing a sample of (each isolated strain cultured) and 1.4 ml of distilled water.
  • the prepared reaction solution was placed in a constant temperature water bath at 30° C., then, 0.3 ml of ethanol was dispensed into the reaction solution and reacted for 5 minutes, and absorbance was measured at 340 nm using a spectrometer.
  • the same amount of distilled water was added instead of the sample.
  • the relative activity of the enzyme was calculated according to the following formula to calculate the concentration of g/L.
  • F is a dilution ratio
  • each isolated strain was cultured in MRS liquid medium at 30°C for 24 hours under anaerobic conditions and centrifuged (4,000 ⁇ 15 minutes, 4°C) After that, the culture supernatant was separated.
  • the reaction solution for measuring ALDH activity was 0.1 ml of ALDH (1 unit, Sigma Chem. Co., USA), 0.3 ml of Tris-HCl buffer (1M, pH 8.8), 0.1 ml of NAD+ (20 mM), 0.1 ml of It was prepared by mixing KCl (3M), 0.33M of 2-mercaptoethanol (2-Mercaptoethanol), 0.1 ml of a sample (each cultured isolated strain) and 2.1 ml of distilled water.
  • the reaction was carried out by adding the same amount of distilled water instead of the sample.
  • the relative activity of the enzyme was calculated according to the following formula to calculate the concentration of g/L.
  • F is a dilution ratio
  • Identification was carried out using 16S ribosomal DNA gene sequencing for strain 125 having excellent alcohol and acetaldehyde decomposition activity.
  • PCR reaction 1 ⁇ l of DNA template (20 ⁇ g/ml), 1.0 ⁇ M forward primer in 10 ⁇ l of Takara Perfect Premix containing 0.4 mM dNTP, 0.5 units Taq polymerase, and 4 mM Mg 2+ and 1.0 ⁇ M reverse primer, 1 ⁇ l each, and distilled water was added to the rest to make a total volume of 20 ⁇ l.
  • PCR amplification was performed with a Mastercycler gradient (Eppendorf, Hamburg, Germany). The PCR reaction was carried out for 30 cycles of 5 minutes at 95° C. (initial denaturation), 45 seconds at 94° C. (denaturation), 45 seconds at 52° C. (annealing), 1 minute at 72° C. (extension), and 5 minutes at 72° C. The final extension was performed.
  • the amplified fragment of 1359bp was bound to a T vector (Invitrogen, Carlsbad, CA, USA) and then transformed.
  • the nucleotide sequence was determined using the T vector sequencing primer, and the ribosomal of GenBank (NCBI, Bethesda, MD, USA) was performed using the BLAST search (http://www.ncbi.nlm.nih.gov) program for the result. It was identified by comparison with the DNA gene sequence.
  • the determined nucleotide sequence was aligned with Clustal_W and BioEdit programs, and the generated gap was treated as a missing trait in the subsequent analysis process.
  • the liver cancer cell line (HepG 2 ) was purchased from ATCC (American Type Culture Collection) and used.
  • the liver cancer cell line (HepG 2 ) was cultured in DMEM-F12 (Dulbecco's Modified Eagle's Medium) medium containing 10% FBS and 1% penicillin-streptomycin.
  • the cells were cultured at 37° C., 5% CO 2 conditions, and the cultured cells were tested by dispensing a constant number of cells (1 ⁇ 10 5 cells/well) in a 24-well plate. After dispensing the cells in a 24-well plate, the cells were used when the cells reached 75% confluence after the cells were completely adhered to the 24-well and took on the shape of the cells.
  • the cultured HepG 2 cells were treated by diluting the Pediococcus inopinatus WiKim0108 strain for 24 hours by concentration, and MTS assay (3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophynyl)-2H-tetrazolium, inner salt; MTS, Promega Co. Madison, WI, USA) at 490 nm with a microplate reader (Molecular Devices, Sunnyvale, CA, USA) Cell viability was measured.
  • MTS assay 3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophynyl)-2H-tetrazolium, inner salt; MTS, Promega Co. Madison, WI, USA
  • the cell viability when treated with the Pediococcus inofinatus WiKim0108 strain of the present invention was found to be almost similar to that of the normal group (N). Therefore, it was found that the Pediococcus inofinatus WiKim0108 strain of the present invention has little cytotoxicity.
  • Example 3 Analysis of ethanol and acetaldehyde content in blood according to ethanol intake, analysis of activity of ADH and ALDH
  • SD rats were supplied from Orient Bio and acclimatized for 7 days, and then the Pediococcus inofinatus WiKim0108 strain of the present invention was used in an experiment to confirm the effect on hangover relieving and alcoholic gastrointestinal diseases according to ethanol intake.
  • 3 animals/crate were bred in a polycarbonate cage for rodents (W235 ⁇ L380 ⁇ H175mM).
  • Ventilation frequency 10 ⁇ 20 times/hr
  • Lighting time 12 hours (lights on at 8:00 am - lights off at 8:00 pm)
  • the temperature, humidity, ventilation frequency and illuminance of the animal room were measured once a week.
  • test group G1: normal group, G2: control group, G3: positive control group, G4: test group
  • group gender number of animals Marie
  • CFU/head ml/head
  • Ethanol (40%, 3g/kg) was orally administered to all experimental groups except for G1 (normal group), and the drug was orally administered once 30 minutes before alcohol administration.
  • Blood was collected through the jugular vein, before and after administration of a sample (Pediococcus inofinatus WiKim0108) and a positive control substance (YM: a commercial substance for relieving hangover) (2 hours and 3 hours after ethanol intake), About 1 ml of blood was collected, injected into a vacuum blood collection tube containing a blood coagulation promoter, left at room temperature for 15 to 20 minutes to coagulate, and then centrifuged at 3,000 rpm for 10 minutes to collect serum. The obtained serum was stored at about -70° C. until analysis of ethanol and acetaldehyde content and analysis of ADH and ALDH activity.
  • a sample Pediococcus inofinatus WiKim0108
  • YM a commercial substance for relieving hangover
  • Ethanol and acetaldehyde contents in serum were analyzed using Megazyme's ELISA assay kit, and ADH and ALSH activity assays were performed using Sigma's ADH (MAK053-1KT) and ALDH (MAK082-1KT) activity assay kit.
  • the area occupied by gastrci pits cells of the alcohol-administered group (G2) compared to the normal group (G1) was statistically significantly reduced, and Pediococcus inofinatus WiKim0108 of the present invention compared to the alcohol-administered group In the group administered with the strain, the area occupied by gastrci pits cells increased statistically and significantly.
  • the area of the submucosa As for the area of the submucosa, the area of the submucosa of the alcohol-administered group (G2) compared to the normal group (G1) increased statistically significantly, and the Pediococcus inofinatus WiKim0108 strain of the present invention compared to the alcohol-administered group In the group administered with , the area of the submucosa was reduced statistically and significantly.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une composition destinée à soulager la gueule de bois, comprenant du Pediococcus inopinatus comme principe actif. En particulier, non seulement le Pediococcus inopinatus WiKim0108 n'a pas de cytotoxicité, mais réduit également la teneur en éthanol et en acétaldéhyde dans le sang qui a été augmentée par l'ingestion d'alcool, augmente efficacement l'activité ADH et ALDH dans le sang, et a une fonction de protection gastro-intestinale. Ainsi, la composition de la présente invention peut être utilisée efficacement comme aliment naturel fonctionnel ou médicament pour soulager la gueule de bois ou les maladies gastro-intestinales alcooliques.
PCT/KR2020/018518 2019-12-17 2020-12-17 Composition destinée à soulager la gueule de bois, contenant du pediococcus inopinatus comme principe actif WO2021125822A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190169062 2019-12-17
KR10-2019-0169062 2019-12-17

Publications (1)

Publication Number Publication Date
WO2021125822A1 true WO2021125822A1 (fr) 2021-06-24

Family

ID=76477833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/018518 WO2021125822A1 (fr) 2019-12-17 2020-12-17 Composition destinée à soulager la gueule de bois, contenant du pediococcus inopinatus comme principe actif

Country Status (2)

Country Link
KR (1) KR102500854B1 (fr)
WO (1) WO2021125822A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010195711A (ja) * 2009-02-25 2010-09-09 Kao Corp バイオフィルム形成促進剤
KR20140134021A (ko) * 2013-05-13 2014-11-21 전라북도(농업기술원) 김치 유래 기능성 유산균 및 이를 이용한 식품
KR101611829B1 (ko) * 2015-06-08 2016-04-14 주식회사 쎌바이오텍 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 페디오코커스 펜토사세우스 cbt sl4 균주 및 이를 포함하는 조성물
KR20180131638A (ko) * 2011-06-10 2018-12-10 프로테라 인코포레이티드 페디오코쿠스를 함유하는 의약 조성물 및 위장병 증후군의 증상을 감소시키기 위한 방법
JP2019201590A (ja) * 2018-05-23 2019-11-28 キッコーマン株式会社 免疫賦活用組成物及びサイトカイン産生促進用組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011209407B2 (en) * 2010-01-28 2014-02-27 Ab-Biotics S.A. Probiotic composition for use in the treatment of bowel inflammation
KR101853603B1 (ko) * 2017-05-18 2018-05-02 주식회사 쎌바이오텍 알코올 또는 아세트알데하이드 분해용 프로바이오틱스를 포함하는 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010195711A (ja) * 2009-02-25 2010-09-09 Kao Corp バイオフィルム形成促進剤
KR20180131638A (ko) * 2011-06-10 2018-12-10 프로테라 인코포레이티드 페디오코쿠스를 함유하는 의약 조성물 및 위장병 증후군의 증상을 감소시키기 위한 방법
KR20140134021A (ko) * 2013-05-13 2014-11-21 전라북도(농업기술원) 김치 유래 기능성 유산균 및 이를 이용한 식품
KR101611829B1 (ko) * 2015-06-08 2016-04-14 주식회사 쎌바이오텍 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 페디오코커스 펜토사세우스 cbt sl4 균주 및 이를 포함하는 조성물
JP2019201590A (ja) * 2018-05-23 2019-11-28 キッコーマン株式会社 免疫賦活用組成物及びサイトカイン産生促進用組成物

Also Published As

Publication number Publication date
KR20210077640A (ko) 2021-06-25
KR102500854B1 (ko) 2023-02-17

Similar Documents

Publication Publication Date Title
WO2018043864A1 (fr) Souche de leuconostoc holzapfelii ayant pour effets de prévenir la perte des cheveux, de favoriser la pousse des cheveux ou d'améliorer la fonction sexuelle, et composition la comprenant
CN110777098B (zh) 一种具有防治糖尿病脑病功效的乳杆菌及其分离方法和应用
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante
WO2018135843A2 (fr) Souche de lactobacillus fermentum pouvant empêcher la perte de cheveux, favoriser la pousse des cheveux, ou améliorer la fonction sexuelle, et composition comprenant cette souche
WO2020076043A1 (fr) Bactéries du microbiote intestinal présentant un effet prophylactique ou thérapeutique contre la dépression, et utilisation correspondante
WO2020226468A1 (fr) Souche de pediococcus inopinatus ｗikim0108 ayant un effet de régulation de la fonction immunitaire et de soulagement d'une maladie intestinale inflammatoire et son utilisation
WO2020226467A1 (fr) Souche d'enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et son utilisation
WO2010131910A2 (fr) Composition pour améliorer la circulation sanguine, et compositions pharmaceutiques et diététiques contenant du thé fermenté
WO2021125822A1 (fr) Composition destinée à soulager la gueule de bois, contenant du pediococcus inopinatus comme principe actif
WO2020116862A1 (fr) Composition pharmaceutique contenant un extrait d'eau florale de lonicera japonica, utilisée dans la prévention ou le traitement d'une nfection à helicobacter pylori
WO2022260335A1 (fr) Composition pour améliorer la population microbienne intestinale comprenant du galactose
WO2023058801A1 (fr) Composition pour soulager, prévenir ou traiter un trouble intestinal, comprenant une souche de lactobacillus acidophilus kbl402 ou kbl409
WO2022139489A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une stéatose hépatique alcoolique et non alcoolique
WO2021015515A1 (fr) Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif
KR102123030B1 (ko) 효모 추출물을 포함하는 당뇨 개선 또는 항산화용 조성물 및 효모 추출물의 제조 방법
WO2021015514A1 (fr) Composition comprenant enterococcus lactis en tant que principe actif pour la prévention, le soulagement, ou le traitement de la stéatose hépatique
CN110839693B (zh) 吉氏副拟杆菌在预防或治疗肥胖或其相关疾病中的应用
WO2020226469A1 (fr) Composition pour la réduction des rides de la peau et l'hydratation de la peau, comprenant enterococcus lactis en tant que composant efficace
WO2016072697A1 (fr) Composition faisant baisser la tension artérielle et contenant en tant que principe actif un exopolysaccharide produit à l'aide de ceriporia lacerata
WO2015122728A1 (fr) Composition anti-tuberculose pour le traitement et la prévention de la tuberculose comprenant un extrait ou de melia azedarach l. ou un extrait de lobelia chinensis lour et des fractions de ceux-ci
WO2019225845A1 (fr) Composition pour soulager le méningiome en utilisant le salidroside et la bétuline
WO2020171256A1 (fr) Souche de lactobacillus ayant un effet inhibiteur de croissance sur un clostridium difficile
WO2023153777A1 (fr) Composition pour soulager la gueule de bois comprenant un extrait de cucumis melo l. en tant que principe actif
WO2019054641A2 (fr) Composition permettant de prévenir et de traiter les troubles gastro-intestinaux comprenant une souche de lactobacillus plantarum
WO2024053761A1 (fr) Composition pour favoriser la prolifération et la différenciation de myoblastes contenant un inhibiteur de l'aldose réductase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20901643

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20901643

Country of ref document: EP

Kind code of ref document: A1